206 related articles for article (PubMed ID: 18053985)
21. Intracellular machinery for matrix degradation in bone-resorbing osteoclasts.
Vääräniemi J; Halleen JM; Kaarlonen K; Ylipahkala H; Alatalo SL; Andersson G; Kaija H; Vihko P; Väänänen HK
J Bone Miner Res; 2004 Sep; 19(9):1432-40. PubMed ID: 15312243
[TBL] [Abstract][Full Text] [Related]
22. Bone-resorbing cells in multiple myeloma: osteoclasts, myeloma cell polykaryons, or both?
Silvestris F; Ciavarella S; De Matteo M; Tucci M; Dammacco F
Oncologist; 2009 Mar; 14(3):264-75. PubMed ID: 19286760
[TBL] [Abstract][Full Text] [Related]
23. Functional osteoclast-like transformation of cultured human myeloma cell lines.
Calvani N; Cafforio P; Silvestris F; Dammacco F
Br J Haematol; 2005 Sep; 130(6):926-38. PubMed ID: 16156862
[TBL] [Abstract][Full Text] [Related]
24. Myeloma bone disease.
Sezer O
Hematology; 2005; 10 Suppl 1():19-24. PubMed ID: 16188625
[TBL] [Abstract][Full Text] [Related]
25. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts.
Kneissel M; Luong-Nguyen NH; Baptist M; Cortesi R; Zumstein-Mecker S; Kossida S; O'Reilly T; Lane H; Susa M
Bone; 2004 Nov; 35(5):1144-56. PubMed ID: 15542040
[TBL] [Abstract][Full Text] [Related]
26. Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation.
Raimondi L; De Luca A; Amodio N; Manno M; Raccosta S; Taverna S; Bellavia D; Naselli F; Fontana S; Schillaci O; Giardino R; Fini M; Tassone P; Santoro A; De Leo G; Giavaresi G; Alessandro R
Oncotarget; 2015 May; 6(15):13772-89. PubMed ID: 25944696
[TBL] [Abstract][Full Text] [Related]
27. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K
Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477
[TBL] [Abstract][Full Text] [Related]
28. Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma.
Breitkreutz I; Raab MS; Vallet S; Hideshima T; Raje N; Chauhan D; Munshi NC; Richardson PG; Anderson KC
Br J Haematol; 2007 Oct; 139(1):55-63. PubMed ID: 17854307
[TBL] [Abstract][Full Text] [Related]
29. Urokinase-induced smooth muscle cell responses require distinct signaling pathways: a role for the epidermal growth factor receptor.
Nicholl SM; Roztocil E; Davies MG
J Vasc Surg; 2005 Apr; 41(4):672-81. PubMed ID: 15874933
[TBL] [Abstract][Full Text] [Related]
30. Erosive arthritis in a patient with pycnodysostosis: an experiment of nature.
Ainola M; Valleala H; Nykänen P; Risteli J; Hanemaaijer R; Konttinen YT
Arthritis Rheum; 2008 Nov; 58(11):3394-401. PubMed ID: 18975331
[TBL] [Abstract][Full Text] [Related]
31. Expression analysis of nha-oc/NHA2: a novel gene selectively expressed in osteoclasts.
Pham L; Purcell P; Morse L; Stashenko P; Battaglino RA
Gene Expr Patterns; 2007 Oct; 7(8):846-51. PubMed ID: 17698421
[TBL] [Abstract][Full Text] [Related]
32. Expression of bone resorption genes in osteoarthritis and in osteoporosis.
Logar DB; Komadina R; Prezelj J; Ostanek B; Trost Z; Marc J
J Bone Miner Metab; 2007; 25(4):219-25. PubMed ID: 17593491
[TBL] [Abstract][Full Text] [Related]
33. Osteoclast nuclei of myeloma patients show chromosome translocations specific for the myeloma cell clone: a new type of cancer-host partnership?
Andersen TL; Boissy P; Sondergaard TE; Kupisiewicz K; Plesner T; Rasmussen T; Haaber J; Kølvraa S; Delaissé JM
J Pathol; 2007 Jan; 211(1):10-7. PubMed ID: 17083146
[TBL] [Abstract][Full Text] [Related]
34. CD44 stimulation by fragmented hyaluronic acid induces upregulation of urokinase-type plasminogen activator and its receptor and subsequently facilitates invasion of human chondrosarcoma cells.
Kobayashi H; Suzuki M; Kanayama N; Nishida T; Takigawa M; Terao T
Int J Cancer; 2002 Dec; 102(4):379-89. PubMed ID: 12402308
[TBL] [Abstract][Full Text] [Related]
35. Proteinase expression during differentiation of human osteoclasts in vitro.
Blair HC; Sidonio RF; Friedberg RC; Khan NN; Dong SS
J Cell Biochem; 2000 Jun; 78(4):627-37. PubMed ID: 10861860
[TBL] [Abstract][Full Text] [Related]
36. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
[TBL] [Abstract][Full Text] [Related]
37. Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin.
Tanaka Y; Abe M; Hiasa M; Oda A; Amou H; Nakano A; Takeuchi K; Kitazoe K; Kido S; Inoue D; Moriyama K; Hashimoto T; Ozaki S; Matsumoto T
Clin Cancer Res; 2007 Feb; 13(3):816-23. PubMed ID: 17289872
[TBL] [Abstract][Full Text] [Related]
38. Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease.
Pennisi A; Li X; Ling W; Khan S; Gaddy D; Suva LJ; Barlogie B; Shaughnessy JD; Aziz N; Yaccoby S
Br J Haematol; 2009 Jun; 145(6):775-87. PubMed ID: 19388929
[TBL] [Abstract][Full Text] [Related]
39. The role of the plasminogen system in bone resorption in vitro.
Daci E; Udagawa N; Martin TJ; Bouillon R; Carmeliet G
J Bone Miner Res; 1999 Jun; 14(6):946-52. PubMed ID: 10352103
[TBL] [Abstract][Full Text] [Related]
40. Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells.
Yang CR; Wang JH; Hsieh SL; Wang SM; Hsu TL; Lin WW
Cell Death Differ; 2004 Jul; 11 Suppl 1():S97-107. PubMed ID: 15002040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
